Terms: = Liver cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Clinical Outcome
5 results:
1. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
[TBL] [Abstract] [Full Text] [Related]
2. Low
Yim SY; Kang SH; Shin JH; Jeong YS; Sohn BH; Um SH; Lee JS
Cells; 2020 Sep; 9(9):. PubMed ID: 32878261
[TBL] [Abstract] [Full Text] [Related]
3. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract] [Full Text] [Related]
4. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.
Yoneda N; Matsui O; Kobayashi S; Kitao A; Kozaka K; Inoue D; Yoshida K; Minami T; Koda W; Gabata T
Jpn J Radiol; 2019 Mar; 37(3):191-208. PubMed ID: 30712167
[TBL] [Abstract] [Full Text] [Related]
5. ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway.
Calderaro J; Nault JC; Bioulac-Sage P; Laurent A; Blanc JF; Decaens T; Zucman-Rossi J
Virchows Arch; 2014 Jan; 464(1):53-60. PubMed ID: 24276407
[TBL] [Abstract] [Full Text] [Related]
